Late-stage data, which showed significant overall and progression-free survival benefits in unresectable hepatocellular carcinoma patients, supports Elevar’s New Drug Application filed in May 2023.
https://www.pharmalive.com/wp-content/uploads/2023/07/liver-tumors.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-07-25 10:27:322023-07-25 10:27:32Elevar touts first-line potential of rivoceranib in Phase III liver cancer trial
